Overview

This study will take place at the primary care center in Milan. Approximately forty outpatients with chronic wounds who are currently treated with a foam dressing will be screened according to predefined inclusion and exclusion criteria. Eligible patients will be enrolled and switched to Mepilex® Border Flex. They will then be followed for approximately 4 weeks after the dressing change, in line with routine clinical practice.

Eligibility

Inclusion Criteria:

• Patients aged 18 years or older.
• The patient has been deemed by the HCP to change dressing to Mepilex® Border Flex.
• Patients with chronic wounds treated with foam dressings, other that Mepilex® Border Flex, according to its intended use at baseline visit for minimum 4 weeks.
• Patients with an expectation of wound follow-up of at least 4 weeks.
• Patients agreeing to only have the dressing changed by the HCP.
• Patients capable of signing the Informed Consent Form and answer the questions being asked.

Exclusion Criteria:

• Patients with any applicable contraindication or sensibilization to any of the dressing compounds
• Patients with pressure ulcers (PU) stage I, deep tissue injuries or terminal wounds (e.g., fungating wounds)
• Patients with wounds whose location and/or aetiology requires a dressing change for reasons that are unrelated to the dressing characteristics such as wounds in the sacral area
• Hospice patients
• Patients participating in other studies interfering with this study
• Patients who have been diagnosed as cognitively impaired